Targeting cancer vasculature via endoglin/CD105: A novel antibody-based diagnostic and therapeutic strategy in solid tumours

Cardiovascular Research

Volumn 86, Issue 1, 2010, Pages 12-19

  Fonsatti, Ester ^a   Nicolay, Hugues J M ^a,b   Altomonte, Maresa ^a   Covre, Alessia ^a,b   Maio, Michele ^a,b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Angiogenesis; Cancer; Endoglin CD105; Monoclonal antibodies; Therapy

Indexed keywords

BEVACIZUMAB; CPG OLIGODEOXYNUCLEOTIDE; ENDOGLIN; ENDOGLIN MONOCLONAL ANTIBODY; GEMCITABINE; INDIUM 111; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 44G4; MONOCLONAL ANTIBODY E9; MONOCLONAL ANTIBODY MAEND3; MONOCLONAL ANTIBODY MJ7; MONOCLONAL ANTIBODY SB6F; MONOCLONAL ANTIBODY SN6; MONOCLONAL ANTIBODY SN6A; MONOCLONAL ANTIBODY SN6H; MONOCLONAL ANTIBODY SN6J; MONOCLONAL ANTIBODY SN6K; MONOCLONAL ANTIBODY TEC11; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIBODY LABELING; AUTORADIOGRAPHY; BLEEDING; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER THERAPY; CELL FUNCTION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HYPERSENSITIVITY; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RADIOACTIVITY; REVIEW; SKIN TUMOR; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BIOLOGICAL MARKERS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 77949370983     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp332     Document Type: Review

References (104)

1. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S et al. Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001;188:1-7.
2. Wong SH, Hamel L, Chevalier S, Philip A. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem 2000;267:5550-5560.
3. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268-275.
4. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995;1:1623-1634.
5. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000;6:2037-2043.
6. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81:568-572.
7. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993;54:363-370.
8. Wang JM, Kumar S, Pye D, Haboubi N, al-Nakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 1994;86:386-388.
9. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-861.
10. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008;14:3785-3791.
11. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11:79-89.
12. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009; [Epub ahead of print] PubMed PMID: 19607914.
13. Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 1986;83: 7898-7902.
14. Bernabeu C, Conley BA, Vary CPH. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007;102:1375-1388.
15. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990;265: 8361-8364.
16. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992;267:19027- 19030.
17. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999;274:584-594.
18. Jovine L, Darie CC, Litscher ES, Wassarman PM. Zona Pellucida domain proteins. Annu Rev Biochem 2005;74:83-114.
19. Llorca O, Trujillo A, Blanco FJ, Bernabeu C. Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J Mol Biol 2007;365:694-705.
20. Lastres P, Martin-Perez J, Langa C, Bernabeu C. Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem J 1994; 301:765-768.
21. Ge AZ, Butcher EC. Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand. Gene 1994;138:201- 206.
22. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P, Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factorbeta. J Biol Chem 1994;269:1995-2001.
23. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B et al. Role of endoglin in cellular response to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 1998;273:33011-33019.
24. Fernández-Ruiz E, St-Jacques S, Bellón T, Letarte M, Bernabéu C. Assignment of the human endoglin gene (END) to 9q34→qter. Cytogenet Cell Genet 1993;64:204-207.
25. Graulich W, Nettelbeck DM, Fischer D, Kissel T, Muller R. Cell type specificity of the human endoglin promoter. Gene 1999;227:55-62.
26. Velasco B, Ramirez JR, Relloso M, Li C, Kumar S, Lopez-Bote JP et al. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther 2001;8:897-904.
27. Cowan PJ, Shinkel TA, Fisicaro N, Godwin JW, Bernabeu C, Almendro N et al. Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation 2003;10: 223-231.
28. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S et al. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993;23: 2340-2345.
29. Perez-Gomez E, Eleno N, Lopez-Novoa JM, Ramirez JR, Velasco B, Letarte M et al. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 2005;24:4450-4461.
30. Qu R, Silver MM, Letarte M. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res 1998;292:333-343.
31. Barresi V, Grosso M, Vitarelli E, Triolo O, Barresi G. Endoglin (CD105) expression in the human heart throughout gestation: an immunohistochemical study. Reprod Sci 2008;15:1018-1026.
32. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534-1537.
33. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008;14: 1931-1937.
34. St-Jacques S, Forte M, Lye SJ, Letarte M. Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 1994;51:405-413.
35. Nagatsuka H, Hibi K, Gunduz M, Tsujigiwa H, Tamamura R, Sugahara T et al. Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinomas. J Oral Pathol Med 2005; 34:70-76.
36. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003;22:6557-6563.
37. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 2000;14:55-64.
38. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002;277: 29197-29209.
39. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004;23:4018-4028.
40. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002;21:1743-1753.
41. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009;19:116-127.
42. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005;204:574-584.
43. Koleva RI, Conley BA, Romero D, Riley KS, Marto JA, Lux A et al. Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J Biol Chem 2006;281:25110-25123.
44. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 1996;133:1109-1121.
45. Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M et al. Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2000;20:2546-2552.
46. Guerrero-Esteo M, Lastres P, Letamendia A, Perez-Alvarez MJ, Langa C, Lopez LA et al. Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol 1999;78:614-623.
47. Diez-Marques L, Ortega-Velazquez R, Langa C, Rodriguez-Barbero A, Lopez-Novoa JM, Lamas S et al. Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta 2002;1587:36-44.
48. Botella LM, Sanz-Rodriguez F, Sanchez-Elsner T, Langa C, Ramirez JR, Vary C et al. Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression. Matrix Biol 2004;22: 561-572.
49. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003;116:2677-2685.
50. Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV et al. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 2006;69:845-854.
51. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004;18: 609-611.
52. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005;96:684-692.
53. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 2007;210:456-468.
54. Jerkic M, Rivas-Elena JV, Santibanez JF, Prieto M, Rodríguez- Barbero A, Perez-Barriocanal F et al. Endoglin regulates cyclooxygenase-2 expression and activity. Circ Res 2006;99:248-256.
55. Lebrin F, Mummery CL. Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2008;18:25-32.
56. van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res 2003;58:20-31.
57. van Laake LW, van den Driesche S, Post S, Feijen A, Jansen MA, Driessens MH et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 2006; 114:2288-2297.
58. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M et al. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer 2003;39: 289-296.
59. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 2002; 21:8272-8281.
60. Jovanovic BD, Huang S, Liu Y, Naguib KN, Bergan RC. A simple analysis of gene expression and variability in gene arrays based on repeated observations. Am J Pharmacogenomics 2001;1:145-152.
61. Wong VC, Chan PL, Bernabeu C, Law S, Wang LD, Li JL et al. Identification of an invasion and tumor-suppressing gene, Endoglin (ENG) silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer 2008;123:2816-2823.
62. Oxmann D, Held-Feindt J, Stark AM, Hattermann K, Yoneda T, Mentlein R. Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene 2008;27:3567-3575.
63. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME. Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol 2000;96:224-228.
64. Saad RS, Jasnosz KM, Tung MY, Silverman JF. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol 2003;22:248-253.
65. Schimming R, Marme D. Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck 2002;24:151-156.
66. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002;31:S109-S113.
67. Düwel A, Eleno N, Jerkic M, Arevalo M, Bolaños JP, Bernabeu C et al. Reduced tumor growth and angiogenesis in endoglin- haploinsufficient mice. Tumour Biol 2007;28:1-8.
68. Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 2003;9: 4221-4226.
69. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 2004;64:4601-4610.
70. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 1995;73:213-220.
71. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 1984;49:405- 413.
72. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000; 36:675-681.
73. Costello B, Li C, Duff S, Butterworth D, Khan A, Perkins M et al. Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 2004;109:436-441.
74. Korpanty G, Grayburn PA, Shohet RV, Brekken RA. Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol 2005;31:1279-1283.
75. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007;13:323-330.
76. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-446.
77. Molema G, Griffioen AW. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol Today 1998;19:392-394.
78. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993;90: 8996-9000.
79. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(Suppl. 3): 11-16.
80. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438: 967-974.
81. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12:356-361.
82. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 2004;108:251-257.
83. Maier JA, Delia D, Thorpe PE, Gasparini G. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 1997;8:238-244.
84. Korn T, Muller R, Kontermann RE. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27:99-106.
85. Volkel T, Holig P, Merdan T, Muller R, Kontermann RE. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004;1663: 158-166.
86. Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Mohammadi M. Production and characterization of a high-affinity nanobody against human endoglin. Hybridoma (Larchmt) 2008;27:353-360.
87. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3:1031-1044.
88. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999;5: 371-382.
89. Tabata M, Kondo M, Haruta Y, Seon BK. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999;82:737-742.
90. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H et al. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 2008;122:2266-2273.
91. Tsujie M, Uneda S, Tsai H, Seon BK. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 2006;29:1087-1094.
92. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by antiendoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001;61:7846-7854.
93. Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009;125:1446-1453.
94. Tan GH, Huang FY, Wang H, Huang YH, Lin YY, Li YN. Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin. World J Gastroenterol 2007;13:2479-2483.
95. Shiozaki K, Harada N, Greco WR, Haba A, Uneda S, Tsai H et al. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother 2006;55:140-150.
96. Muñoz R, Arias Y, Ferreras JM, Rojo MA, Gayoso MJ, Nocito M et al. Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b. Cancer Lett 2007;256:73-80.
97. Rosen L, Gordon MS, Hurwitz HI, Wong MK, Adams BJ, Alvarez D et al. Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer (Abstract 3518). J Clin Oncol 2009;27(Suppl.):15s.
98. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984-992.
99. Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A. Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001;94:579-585.
100. Seon BK. Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer 2002; 99:310-311.
101. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995;36:237-251.
102. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Endoglin/CD105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 1996;39: 239-242.
103. Maio M, Altomonte M, Fonsatti E. Is it the primetime for endoglin (CD105) in the clinical setting? Cardiovasc Res 2006;69:781-783.
104. Calabrò L, Di Giacomo AM, Altomonte M, Fonsatti E, Mazzei MA, Volterrani L et al. Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res 2007;26:145- 150.